JP2020507569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507569A5 JP2020507569A5 JP2019542717A JP2019542717A JP2020507569A5 JP 2020507569 A5 JP2020507569 A5 JP 2020507569A5 JP 2019542717 A JP2019542717 A JP 2019542717A JP 2019542717 A JP2019542717 A JP 2019542717A JP 2020507569 A5 JP2020507569 A5 JP 2020507569A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- use according
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457219P | 2017-02-10 | 2017-02-10 | |
| US62/457,219 | 2017-02-10 | ||
| PCT/IB2018/050783 WO2018146612A1 (en) | 2017-02-10 | 2018-02-08 | 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507569A JP2020507569A (ja) | 2020-03-12 |
| JP2020507569A5 true JP2020507569A5 (enExample) | 2021-03-18 |
| JP7161481B2 JP7161481B2 (ja) | 2022-10-26 |
Family
ID=61274309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542717A Active JP7161481B2 (ja) | 2017-02-10 | 2018-02-08 | １－（４－アミノ－５－ブロモ－６－（１ｈ－ピラゾール－１－イル）ピリミジン－２－イル）－１ｈ－ピラゾール－４－オール及びがんの治療におけるその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11078191B2 (enExample) |
| EP (1) | EP3579874B1 (enExample) |
| JP (1) | JP7161481B2 (enExample) |
| KR (1) | KR20190115053A (enExample) |
| CN (1) | CN110290808B (enExample) |
| AU (2) | AU2018217963B2 (enExample) |
| CA (1) | CA3051986A1 (enExample) |
| DK (1) | DK3579874T3 (enExample) |
| ES (1) | ES2893006T3 (enExample) |
| HU (1) | HUE057337T2 (enExample) |
| IL (1) | IL268549B (enExample) |
| PL (1) | PL3579874T3 (enExample) |
| PT (1) | PT3579874T (enExample) |
| SI (1) | SI3579874T1 (enExample) |
| WO (1) | WO2018146612A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12019502703A1 (en) * | 2017-05-31 | 2020-10-26 | Novartis Ag | Crystalline forms of 5-bromo-2,6-di(1h-pyrazol-1-yl) pyrimidin-4-amine and new salts |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US7119200B2 (en) * | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| CA2736829C (en) | 2008-09-12 | 2018-02-27 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| EP2545078A1 (en) | 2010-03-11 | 2013-01-16 | UCB Pharma, S.A. | Pd-1 antibody |
| ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RU2604814C2 (ru) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Варианты гуманизированных иммуномодулирующих моноклональных антител |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN105658206A (zh) * | 2013-06-03 | 2016-06-08 | 诺华股份有限公司 | 抗pd-l1抗体与mek抑制剂和/或braf抑制剂的组合 |
| US20160145355A1 (en) | 2013-06-24 | 2016-05-26 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| GB201320729D0 (en) * | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| WO2016061142A1 (en) | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US10561653B2 (en) | 2015-08-11 | 2020-02-18 | Novartis Ag | 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer |
-
2018
- 2018-02-08 CN CN201880011779.3A patent/CN110290808B/zh not_active Expired - Fee Related
- 2018-02-08 AU AU2018217963A patent/AU2018217963B2/en not_active Ceased
- 2018-02-08 PT PT18707151T patent/PT3579874T/pt unknown
- 2018-02-08 SI SI201830420T patent/SI3579874T1/sl unknown
- 2018-02-08 US US16/484,183 patent/US11078191B2/en not_active Expired - Fee Related
- 2018-02-08 KR KR1020197025984A patent/KR20190115053A/ko not_active Abandoned
- 2018-02-08 CA CA3051986A patent/CA3051986A1/en active Pending
- 2018-02-08 HU HUE18707151A patent/HUE057337T2/hu unknown
- 2018-02-08 ES ES18707151T patent/ES2893006T3/es active Active
- 2018-02-08 DK DK18707151.9T patent/DK3579874T3/da active
- 2018-02-08 WO PCT/IB2018/050783 patent/WO2018146612A1/en not_active Ceased
- 2018-02-08 JP JP2019542717A patent/JP7161481B2/ja active Active
- 2018-02-08 EP EP18707151.9A patent/EP3579874B1/en active Active
- 2018-02-08 PL PL18707151T patent/PL3579874T3/pl unknown
-
2019
- 2019-08-06 IL IL268549A patent/IL268549B/en unknown
-
2020
- 2020-10-19 AU AU2020256467A patent/AU2020256467B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250213684A1 (en) | Combination therapies comprising antibody molecules to tim-3 | |
| JP7695819B2 (ja) | Ｐｄ－ｌ１に対する抗体分子およびその使用 | |
| US20260021178A1 (en) | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor | |
| JP7770760B2 (ja) | ヒトｒｏｒ１に対する抗体を含む抗体－薬物コンジュゲートおよびその使用 | |
| EP3411398B1 (en) | Targeted therapeutic agents and uses thereof | |
| CN107148285B (zh) | 吡咯并苯并二氮杂䓬-抗体缀合物 | |
| US20220144943A1 (en) | Anti-cd47 antibodies and uses thereof | |
| WO2020130125A1 (ja) | 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| JP2021523122A5 (enExample) | ||
| JP2019503349A5 (enExample) | ||
| JP2017186337A5 (enExample) | ||
| JP2020527572A5 (enExample) | ||
| JP2022513420A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2019517549A5 (enExample) | ||
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| JP2020500834A5 (enExample) | ||
| JP2023515675A5 (enExample) | ||
| JP2023510199A5 (enExample) | ||
| TW201836610A (zh) | Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案 | |
| TW202216207A (zh) | 抗體-藥物結合物及cdk9抑制劑之組合 | |
| JP2020523414A (ja) | Ｌｇｒ５に結合する抗体薬物複合体 | |
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2021501800A (ja) | 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法 | |
| JP2020505350A5 (enExample) |